Wednesday, January 20, 2021
Home Covid-19 Britain Authorizes Covid-19 Vaccine From Oxford and AstraZeneca

Britain Authorizes Covid-19 Vaccine From Oxford and AstraZeneca


These setbacks have not dampened enthusiasm in #Britain for the country’s leading homegrown vaccine, one that analysts have said could right the course of #Prime #Minister #Boris #Johnson’s careening tenure if it is rolled out quickly.

#Having ordered 100 million doses, 40 million of which are supposed to be available by #March, #Britain has made the #AstraZeneca shot the linchpin of its vaccination strategy. #Since authorizing #Pfizer’s vaccine on #Dec. 2, #Britain has used it to vaccinate hundreds of thousands of people. #But the country has struggled to administer it beyond hospitals and doctor’s offices, leaving some of its highest-priority recipients, like nursing home residents, still vulnerable.

A small number of volunteers in the clinical trial in #Britain received their first dose at half strength because of a measurement problem. #Oxford had hired an outside manufacturer to produce the vaccine for the trial. #But when researchers received a sample of the vaccine, they found its strength to be twice as high as what the manufacturer had found using a different measurement technique. #Not knowing which measurement to trust, the researchers decided to cut the dose in half to ensure that volunteers wouldn’t get double the dose originally intended. #Later, the #Oxford researchers confirmed that their reading was too high, and they switched back to the originally planned dose for the second shot.

- Advertisement -

#In the smaller group of 2,741 people who received the half-strength first dose or a meningococcal vaccine as a control, the vaccine was found to have 90 percent efficacy. #None of those participants were over the age of 55, however, making it difficult to know if those results would hold in older people.

#AstraZeneca and #Oxford scientists have said that they do not know why the half-strength initial dose was so much more effective. #But they have voiced confidence in their results, particularly the finding that no one who received the vaccine in the clinical trials developed severe #Covid-19 or was hospitalized.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” #Pascal #Soriot, #AstraZeneca’s chief executive, told The #Times of #London in an interview published on #Saturday. The company has released no evidence of efficacy rates as high as #Pfizer or #Moderna’s. “I can’t tell you more because we will publish at some point,” #Mr. #Soriot told The #Times.

#Oxford scientists earlier this month published interim findings from the vaccine’s clinical trials in The #Lancet. #Forthcoming final results from those trials are not expected to be significantly different from the interim data, as is typical in clinical research.



[ source link ]
https://www.nytimes.com/2020/12/30/world/europe/britain-authorizes-covid-19-vaccine-from-oxford-and-astrazeneca.html

##Britain ##Authorizes ##Covid19 ##Vaccine ##Oxford ##AstraZeneca

- Advertisement -
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments